Search research articles
Contact Us
Filters
Showing results (1-10 of 35) with videos related to
Page
of 4
Sort By:
Journal of Clinical Pharmacology
|
September 25, 2008
Pharmacologic consideration for the use of antiretroviral agents in the elderly
Martin S Rhee, David J Greenblatt
Current Opinion in HIV and AIDS
|
December 6, 2021
Lenacapavir: a first-in-class HIV-1 capsid inhibitor
Hadas Dvory-Sobol, Naveed Shaik, Christian Callebaut, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 24, 2008
Risk factors for proteinuria in HIV-infected and -uninfected Hispanic drug users
Martin S Rhee, Christopher H Schmid, Lesley A Stevens, et al.
Journal of Clinical Pharmacology
|
January 26, 2010
Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir)
Martin S Rhee, James A Hellinger, Sandy Sheble-Hall, et al.
AIDS and Behavior
|
March 10, 2025
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV
Moti Ramgopal, Dylan J Mezzio, Keith Dunn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 25, 2022
Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus
Iro Chatzidaki, Tristan Curteis, Hannah Luedke, et al.
Antiviral Therapy
|
October 17, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
Kirsten L White, Rima Kulkarni, Damian J McColl, et al.
The Journal of Infectious Diseases
|
September 9, 2022
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
Nicolas A Margot, Vidula Naik, Laurie VanderVeen, et al.
Clinical Pharmacology in Drug Development
|
January 23, 2025
Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration
Renu Singh, Mark Shelton, Isabel Olson, et al.
The Lancet. Child & Adolescent Health
|
September 1, 2018
Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial
Eva Natukunda, Aditya H Gaur, Pope Kosalaraksa, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 35) with videos related to
Sort By:
Page
of 4
Journal of Clinical Pharmacology
|
September 25, 2008
Pharmacologic consideration for the use of antiretroviral agents in the elderly
Martin S Rhee, David J Greenblatt
Current Opinion in HIV and AIDS
|
December 6, 2021
Lenacapavir: a first-in-class HIV-1 capsid inhibitor
Hadas Dvory-Sobol, Naveed Shaik, Christian Callebaut, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
June 24, 2008
Risk factors for proteinuria in HIV-infected and -uninfected Hispanic drug users
Martin S Rhee, Christopher H Schmid, Lesley A Stevens, et al.
Journal of Clinical Pharmacology
|
January 26, 2010
Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir)
Martin S Rhee, James A Hellinger, Sandy Sheble-Hall, et al.
AIDS and Behavior
|
March 10, 2025
Participant-reported Outcomes from the CAPELLA Clinical Trial of Lenacapavir-based Regimens in Heavily Treatment-experienced Adults with HIV
Moti Ramgopal, Dylan J Mezzio, Keith Dunn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 25, 2022
Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus
Iro Chatzidaki, Tristan Curteis, Hannah Luedke, et al.
Antiviral Therapy
|
October 17, 2014
Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients
Kirsten L White, Rima Kulkarni, Damian J McColl, et al.
The Journal of Infectious Diseases
|
September 9, 2022
Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir
Nicolas A Margot, Vidula Naik, Laurie VanderVeen, et al.
Clinical Pharmacology in Drug Development
|
January 23, 2025
Effect of Food Intake or Coadministration With an Acid-Reducing Agent on Lenacapavir Pharmacokinetics Following Oral Administration
Renu Singh, Mark Shelton, Isabel Olson, et al.
The Lancet. Child & Adolescent Health
|
September 1, 2018
Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial
Eva Natukunda, Aditya H Gaur, Pope Kosalaraksa, et al.
Page
of 4